The New Backbone of Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer – Animated Whiteboard View
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
US Oncology Network
This enduring activity is focused on the care of patients with hormone receptor-positive, HER2-negative breast cancer.
This CME initiative is designed to meet the educational needs of medical oncologists, nurse practitioners,
nurses, pharmacists, and other healthcare providers involved in the treatment of patients with hormone
receptor-positive, HER2-negative advanced breast cancer.
After completing the CME activity, learners should be better able to:
- Describe the involvement of CDKs and cyclins in the uncontrolled cellular proliferation characteristic of breast cancer
- Review how to use patient and disease characteristics to identify the individual with advanced, HR+ breast cancer who would benefit from the use of CDK 4/6 inhibition
- Analyze the properties of CDK 4/6 inhibitors and the potential pharmacodynamic effects in patients
with hormone receptor positive, HER2-negative advanced breast cancer
- Discuss the application of CDK 4/6 inhibitor clinical trial data to the management of breast cancer
patients in a community oncology practice
- Explain the patient’s and healthcare team’s responsibilities that will foster a multidisciplinary effort to
ACCREDITATION AND DESIGNATION STATEMENTS
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s) TM . Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer. Credits: 1.0 ANCC Contact Hour(s)
CNE Accreditation Statement
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. O’Shaughnessy is a consultant for AstraZenea, Novartis, Pfizer, Lilly, and Celgene.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose
Staff, Planners and Managers
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.
Participants will receive their certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: March 11, 2019
EXPIRATION DATE: March 11, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.